Are cardiac risks of rosiglitazone legitimate?
The article highlights the 67th Annual Scientific Sessions of the American Diabetes Association (ADA) held in Chicago, Illinois. Physician Steven E. Nissen discusses the results of a meta-analysis showing excess hazard of myocardial infarction found with rosiglitazone. Physician Timothy Davis presents his analysis of patients with type 2 diabetes showing that statins and fibrates lower the risk of peripheral neuropathy. Physican Harold Bays discusses his study of colesevelam HCl.
Related Questions
- How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?
- Does a Living Will mean the person is not to be resuscitated in the event of a cardiac and / or respiratory arrest?
- Whats the definition of cardiac index in cardiac output monitoring?
